(Q44911707)

English

The clinical benefit of bevacizumab in metastatic colorectal cancer is independent of K-ras mutation status: analysis of a phase III study of bevacizumab with chemotherapy in previously untreated metastatic colorectal cancer

scientific article

Statements

The clinical benefit of bevacizumab in metastatic colorectal cancer is independent of K-ras mutation status: analysis of a phase III study of bevacizumab with chemotherapy in previously untreated metastatic colorectal cancer (English)
Herbert I Hurwitz
William Ince
William F Novotny
Oliver Rosen
14 January 2009

Identifiers

 
edit
    edit
      edit
        edit
          edit
            edit
              edit
                edit
                  edit